CA-SKYHIVE/DEUTSCHE
11.4.2022 13:02:07 CEST | Business Wire | Press release
SkyHive, a workforce technology innovator that delivers powerful insights for improved human capital management (HCM), today announced that Deutsche Bank, Germany’s leading bank, has made a sizable equity investment in the company via its strategic Corporate Venture Capital unit. The funding coincides with SkyHive’s European incorporation and increasing demand from multinational customers.
Michael Ilgner, Global Head of HR & Real Estate at Deutsche Bank, said: “Using data intelligently and with purpose will take human capital management to the next level. SkyHive is addressing a key talent shortage issue observed across all industries and particularly prevalent in financial services. Its value proposition of providing employers with a better understanding of the skills of their workforce and in the market paves the way for improved resource management, workforce upskilling, and employee retention.”
Gil Perez, Chief Innovation Officer at Deutsche Bank and Head of Deutsche Bank Corporate Venture Capital, said: “We are delighted to invest, partner and collaborate with SkyHive. Deutsche Bank’s digital transformation has accelerated the pace and scale we need to upskill our workforce, attract, and recruit the best talent in the market. Our ability to effectively and continually invest in our current and future employees is an integral part of our digital transformation.”
In addition to the investment, SkyHive has invited Karen Meyer, Chief Operating Officer for Deutsche Bank’s HR organization, to participate in SkyHive’s Board of Directors meetings in a non-voting observer capacity.
SkyHive.ai, a Certified B Corporation, combines its real-time, global labor market data with transparent and unbiased artificial intelligence to give companies, government and educators actionable insights into their workforce’s current and emerging skills, skills gaps, industry benchmarks and reskilling options. SkyHive uses a two-pronged approach: skills-first applications and extensible platforms that normalize skills intelligence for companies across existing HCM ecosystems. For individuals, SkyHive’s Skills Passport provides data, insights and upskilling options to ensure users’ skills stay relevant, both today and well into the future.
“Human capital is by far the most untapped potential in today’s modern age,” said SkyHive Founder and CEO Sean Hinton. “Enterprises and communities that are alert to the advancements in strategic workforce solutions can radically transform top and bottom-line growth trajectories by unleashing their workforce’s full capacity. Who you hire, where you hire, what you pay, who you deploy and how you compete are just a few examples of key business decisions that hinge on a deep, continuous and accurate understanding of your constituents’ skills. Our technology uniquely enables this mission-critical capability, and therefore was a strong rationale for Deutsche Bank’s investment.”
The investment from Deutsche Bank will support SkyHive’s growing global operations, particularly the company’s continued expansion in the European market. SkyHive also maintains ongoing partnerships with the likes of World Economic Forum, Workday and Accenture.
About SkyHive
SkyHive is a Certified B Corporation and software provider of global workforce intelligence technology, optimizing labor market efficiencies in real-time for companies, communities, and national economies. Leading enterprises use SkyHive’s cloud-based applications and platforms to power the future of work at its most granular level: skills. SkyHive’s Quantum Labor Analysis™ has been recognized by the World Economic Forum, Gartner, and Forbes for leading efforts in ethical AI and its positive impact on labor economies worldwide. For more information, visit www.skyhive.ai .
About Deutsche Bank
Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany’s leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific. For more information, visit www.db.com .
About Deutsche Bank Corporate Venture Capital
Deutsche Bank Corporate Venture Capital (CVC) is a cross-divisional & global activity to support startups and entrepreneurs. For more information, visit db.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005263/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom